Article Versions Notes

Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux S-C, Mihaila L, Dupont H, Junot H, Bunel V, Grall N, et al. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. Microorganisms. 2021; 9(2):282. https://doi.org/10.3390/microorganisms9020282

Bleibtreu, Alexandre, Laurent Dortet, Remy A. Bonnin, Benjamin Wyplosz, Sophie-Caroline Sacleux, Liliana Mihaila, Hervé Dupont, Helga Junot, Vincent Bunel, Nathalie Grall, and et al. 2021. "Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study" Microorganisms 9, no. 2: 282. https://doi.org/10.3390/microorganisms9020282

Bleibtreu, A., Dortet, L., Bonnin, R. A., Wyplosz, B., Sacleux, S.-C., Mihaila, L., Dupont, H., Junot, H., Bunel, V., Grall, N., Razazi, K., Duran, C., Tattevin, P., Dinh, A., & on behalf of the Cefiderocol French Study Group. (2021). Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. Microorganisms, 9(2), 282. https://doi.org/10.3390/microorganisms9020282